Ariceum Therapeutics

Listen in as our COO Greg Mullen, PhD, FRSC speaks with Stephen Adams of Optimum Strategic Communications in the latest #optimumtv 📺 episode! Greg provides insight into #Ariceum’s first-in-human Phase 1 trial, CITADEL-123 conducted at University College London Hospitals NHS Foundation Trust (#UCLH) for patients with recurrent #glioblastoma brain cancer. Ariceum is the first company ever to sponsor a clinical trial of Auger therapy. 👀 Watch the full episode below 👇 and follow Ariceum on LinkedIn to learn more about Ariceum and its proprietary drug, ¹²³I-ATT001, an iodine radiolabelled PARP inhibitor that emits low energy Auger electrons that are very potent over short distances for the potential treatment of patients with recurrent glioblastoma. #biotech #oncology #lifesciences #ATT001 #BrainTumour 

This week is #BrainTumourAwarenessWeek which we at #Ariceum fully support, with a focus on recurrent #glioblastoma, an aggressive form of brain #cancer with a high unmet medical need. Ariceum is striving to develop a much-needed therapy for this devastating form of #braincancer, having commenced our Phase 1 first-in-human trial (CITADEL-123) of ¹²³I-ATT001, Ariceum's Iodine-123 labelled PARP inhibitor, in patients with recurrent glioblastoma. Find out more information about Ariceum's CITADEL-123 Phase 1 trial conducted at University College London Hospitals NHS Foundation Trust (#UCLH) on our website linked in the comments below 👇 #biotech #oncology #lifesciences #ATT001 #BrainTumourAwareness

📢 #Ariceum is pleased to announce that it presented outstanding data on its proprietary radiolabelled peptide SS0110 (#satoreotide) in a Top-Rated Oral Presentation at European Association of Nuclear Medicine (EANM) Annual Conference. ²²⁵Ac-Satoreotide is a first-in-class somatostatin receptor 2 antagonist targeting extensive stage small cell lung cancer (#SCLC).   Highlights: 🔎 Satoreotide expressed a superior pharmacokinetic profile relative to DOTA-TATE with a higher pre-clinical anti-tumour efficacy, irrespective of radionuclide used 💡 100% survival with a single dose of 30 kBq ²²⁵Ac-satoreotide but not with ²²⁵Ac-DOTA-TATE   Learn more about Ariceum's presentation and ²²⁵Ac-Satoreotide, the first antagonist labelled with ²²⁵Ac to enter clinical development, in the press release linked in the comments 👇 #EANM #EANM24 #EANM2024 #biotech #oncology #lifesciences #oncology #cancer

📢 #Ariceum is showcasing its first-in-class, lead #radiopharmaceutical drug #satoreotide in an oral presentation at the European Association of Nuclear Medicine (EANM) (#EANM) Annual Congress in Germany! 🕔 Prachi Desai, Scientist at Ariceum, will be presenting an oral presentation entitled, “²²⁵Ac-SSO110 induces long-lasting anti-tumour responses in contrast to ²²⁵Ac-DOTA-TATE and ¹⁶¹Tb-DOTA-TATE in the treatment of SSTR2-positive tumour xenografts”, at 09:00 AM – 09:10 AM CEST on Tuesday 22nd October. Session time: 08:00 AM – 09:30 AM CEST Presentation number: OP-533 Session number: 1204 Listen in as Prachi demonstrates outstanding data on #satoreotide, highlighting its potential to clinically outperform SSTR2 targeting agonists across multiple indications expressing SSTR2, including small cell lung cancer (#SCLC) and pancreatic cancers. The international scientific conference is taking place from 19-23 October in Hamburg, presenting a valuable opportunity to discuss the latest theranostic advances 🤝, impressive clinical evidence 📈, as well as recently developed #radiopharmaceuticals, novel imaging, and detection technologies.   #EANM2024 #EANM24 #biotech #oncology #lifesciences #ATT001 #ATT002 #satoreotide #oncology #cancer

📢 #Ariceum is showcasing its first-in-class, lead #radiopharmaceutical drug #satoreotide in an oral presentation at the European Association of Nuclear Medicine (EANM) (#EANM) Annual Congress in Germany! 🕔 Prachi Desai, Scientist at Ariceum, will be presenting an oral presentation entitled, “²²⁵Ac-SSO110 induces long-lasting anti-tumour responses in contrast to ²²⁵Ac-DOTA-TATE and ¹⁶¹Tb-DOTA-TATE in the treatment of SSTR2-positive tumour xenografts”, at 09:00 AM – 09:10 AM CEST on Tuesday 22nd October. Session time: 08:00 AM – 09:30 AM CEST Presentation number: OP-533 Session number: 1204 Listen in as Prachi demonstrates outstanding data on #satoreotide, highlighting its potential to clinically outperform SSTR2 targeting agonists across multiple indications expressing SSTR2, including small cell lung cancer (#SCLC) and pancreatic cancers. The international scientific conference is taking place from 19-23 October in Hamburg, presenting a valuable opportunity to discuss the latest theranostic advances 🤝, impressive clinical evidence 📈, as well as recently developed #radiopharmaceuticals, novel imaging, and detection technologies.   #EANM2024 #EANM24 #biotech #oncology #lifesciences #ATT001 #ATT002 #satoreotide #oncology #cancer

Are you attending #EANO2024? Meet Austin Smith and CAROL ANDREA PREGONERO GAMEZ, PhD at the 19th Meeting of the EANO European Association of Neuro-Oncology! 📍 Austin and Carol will be in Glasgow, UK, from 17-20 October for the congress which aims to bridge gaps in the sector's understanding and management of central nervous system tumours. 💡 Get in touch to arrange a meeting with the team to find out more about Ariceum's novel iodine radiolabelled PARP inhibitor #ATT001, which is in clinical development in patients with recurrent #glioblastoma in a first-in-human Phase 1 trial, CITADEL-123. #biotech #radiopharmaceuticals #ATT001 #ATT002 #satoreotide #oncology #cancer #EANO

We're #hiring a new IT Manager (m/f/x) in Berlin. Apply today or share this post with your network.

To mark Nuclear Medicine and Molecular Imaging Week, #Ariceum celebrates its team and their contributions to developing novel #radiopharmaceuticals, a key component of #nuclearmedicine to visualize and treat #cancer. Radiopharmaceuticals are used in diagnostic imaging procedures to produce non-invasive images of organs and tissues and also to treat malignancies. The theme for this year is “See it. Believe it. Treat it." #lifesciences #biotech #ATT001 #ATT002 #oncology #radiopharmaceuticals #cancer

In our final clip from WuXi AppTec's BOLD series, Ariceum CEO, Manfred Ruediger, discusses why simple animal models are an essential prerequisite for going into the clinic with #noveldrugcandidates, stressing their importance in establishing mechanism of action and a potential starting dose. Good models for immune-related questions remain scarce however...   Manfred's full interview can be found at: https://lnkd.in/gpzns2-Q   #biotech #immunotherapy #radiopharmaceuticals

💡 This week, #Ariceum's CMO, Germo Gericke, is joining a panel discussion and will be presenting on Ariceum at the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference!   We are excited to be attending the conference, held on 26th September in New York, and look forward to an insightful discussion and networking with other attendees there!   Get in touch to organise a meeting with Ariceum at the event or to find out more about our pipeline of #radiopharmaceutical products for hard-to-treat cancers.   #lifesciences #biotech #satoreotide #ATT001 #ATT002 #oncology #radiopharmaceuticals #cancer